Cognition Therapeutics, Inc. cash flow to debt ratio of -3.85K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cognition Therapeutics, Inc.'s free cash flow has increased -13.66% from $-28.48M last year to $-24.59M, signaling increasing performance

Cognition Therapeutics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Cognition Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.02 today, signaling strengthened financials

Cognition Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Cognition Therapeutics, Inc.'s interest coverage ratio is -3.30K, which means that the company struggles to meet interest obligations, signaling financial risk.

Cognition Therapeutics, Inc. has insufficient data to evaluate this check.

Cognition Therapeutics, Inc.'s short-term assets of $47.99M exceed its short-term liabilities of $13.92M

Cognition Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cognition Therapeutics, Inc.'s return on equity of -72.68%, is lower than 15.00%, indicating bad performance

Cognition Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cognition Therapeutics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Cognition Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cognition Therapeutics, Inc. has negative free cash flow, indicating cash burn

Cognition Therapeutics, Inc.'s yearly earnings has increased -30.86% since last year from $-33.97M to $-23.49M, signaling increasing performance

Cognition Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -141.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cognition Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Cognition Therapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Cognition Therapeutics, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Cognition Therapeutics, Inc. has insufficient data to evaluate this check.

Cognition Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cognition Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cognition Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cognition Therapeutics, Inc. has insufficient data to evaluate this check.

Cognition Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cognition Therapeutics, Inc. has a price-to-book ratio of 3.34x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cognition Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue